Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer

OBJECTIVES: To assess the impact of patient age and weight on the pharmacokinetics (PK), testosterone (T) suppression and safety from four fixed dosing regimens (7.5, 22.5, 30, or 45 mg for 1‐, 3‐, 4‐, or 6‐months, respectively) of subcutaneous in situ gel delivered leuprolide acetate (Gel‐LA) injec...

Descripción completa

Detalles Bibliográficos
Autores principales: Renzulli, Joseph F., Tagawa, Scott T., Atkinson, Stuart N., Boldt‐Houle, Deborah M., Moul, Judd W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988824/
https://www.ncbi.nlm.nih.gov/pubmed/35474709
http://dx.doi.org/10.1002/bco2.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988824/
https://www.ncbi.nlm.nih.gov/pubmed/35474709
http://dx.doi.org/10.1002/bco2.13

Ejemplares similares